2023 AGM Presentations
Released
Released
Announcement PDF
ASX Announcement
30 November 2023
2023 AGM
Chair’s Address and CEO’s Presentation
Microba Life Sciences Limited (ASX:MAP) ("Microba" or "the Company") is pleased to attach the Chair’s Address and CEO’s
Presentation to be delivered at the 2023 Annual General Meeting of Shareholders of the Company to be held today at 11.00 am
Brisbane time.
Shareholders wishing to attend the Annual General Meeting in person can find the details in the Notice of Meeting as lodged with
the ASX on 30 October 2023 and available at the Company’s website at ir.microba.com.
This announcement has been authorised for release by the Chair and CEO.
For further information, please contact:
Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com
Investor / Media Relations
E: investor@microba.com
W: https://ir.microba.com/
Join our Investor Mailing List
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology
for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for
major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers.
Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the
microbiome, health and disease for the development of new health solutions.
not subject to, the registration requirements of the US Securities Act and applicable securities laws of any state or other
jurisdiction of the United States
For more information visit: www.microba.com
Microba encourages all current investors to go paperless by registering their details with the designated registry service
provider, Automic Group.
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
30 November 2023
Chair’s Address to Annual General Meeting
Welcome to the 2023 AGM of Microba Life Sciences. Professor Ian Frazer has been unable to join today, so Dr.
Luke Reid and I will address the meeting.
Microba has now entered its second year as a publicly listed company and continues to maintain it steadfast
vision of the human gut microbiome representing one of the biggest untapped opportunities to improve human
health. Unfortunately, it has been a second difficult year for the globally listed biotechnology companies. After
beginning a gradual recovery from the low enterprise level in June 2022, the global biotechnology sector fell
again in 2023. Valuations of many listed biotechnology companies are down significantly since the peak. This is
important to note, but more importantly the team at Microba believes more than ever in the long-term
fundamentals of biotechnology innovation and is continuing to advance both our testing services and
therapeutic development activities to unlock the health and commercial opportunity from the human
microbiome.
Microba commenced operations in 2018 providing gut microbiome profiling to consumers, clinicians and
researchers in Australia. Fast forward to today, the Company and the microbiome sector have made several
significant advances. In October 2022, we announced an expansion and extension of our testing services
distribution agreement with SYNLAB, Europe’s largest pathology company. In December 2022, we were
delighted to also announce a strategic shareholding and commercial testing services partnership with global
medical diagnostics leader Sonic Healthcare. The partnerships align the intent of the companies to bring
microbiome testing into the hands of clinicians and patients across the globe.
In February 2023, we launched the most comprehensive gastrointestinal testing solution available to healthcare
professionals, MetaXplore. The test is currently available to clinicians in Australia. Furthermore, Microba
announced the upcoming launch of the advanced infectious disease test, MetaPanel with Sonic Healthcare in
Australia. Following the domestic launch, we intend to take the technology into the United States.
FY23 was a year of significant advancement for the Microba therapeutic division and the microbiome sector. In
November 2022, the FDA approved Reboyta, the first ever faecal microbiome product and in April 2023, the FDA
approved Vowst, the first oral microbiome therapeutic. These approvals have confirmed a regulatory pathway
for the approval of live bio-therapeutic drug candidates for the microbiome sector. For Microba, FY23 is the year
that the Company became a clinical stage drug development company, three years after the establishment of
the therapeutic division. In June 2023 we commenced a Phase 1 clinical trial for Microba’s Inflammatory Bowel
Disease program with lead candidate MAP 315. The trial has completed dosing, with the final read out expected
in December 2023. The Company has also used it’s pre-clinical research capability to progress microbiome
candidates from discovery to generation of pre-clinical data in Immuno-oncology and Autoimmune diseases.
Post the completion of FY23 year, the Company announced the acquisition of Invivo Clinical, a commercial stage
microbiome testing and product company based in the United Kingdom, one of the key countries for Microba
Life Sciences international growth strategy. The Company would like to welcome the thirty-three employees
from Invivo to the Microba group and we will have more to say about Invivo post expected completion in
December 2023.
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
30 November 2023
As mentioned earlier, despite the negative performance of the global biotechnology sector in 2023, Microba is
well positioned to accelerate growth in FY24 both domestically and in international markets. The Company has
strategically positioned itself at the forefront of microbiome testing and the continued growth in testing
revenues. In Therapeutics, the Company has a clinical stage drug candidate for IBD, is advancing its Immunooncology program and on track to soon complete its two-year pre-clinical Autoimmune discovery program with
Gingo Bioworks.
Professor Frazer and I would like to thank our fellow board members, executives, and employees for their hard
work during the year. We would also like to say thank you to our customers and shareholders for their
significant support in FY23. Microba Life Sciences will have a positive impact on human lives globally when we
are successful in achieving our goals.
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
Transforming health through
the human microbiome
Microba Annual General Meeting 2023
30 November 2023
| Achievements & Upcoming catalysts
Recent Achievements
• Next generation healthcare test,
MetaXplore™ launched in Australia with
strong uptake
• First agreement executed to deliver
Microba’s advanced infectious disease
testing technology MetaPanel™ into Australia
• Phase I trial commenced for IBD lead drug
candidate transitioning Microba to a clinical
stage drug development Company
• Positive first animal model data generated
under the Company’s Immuno-Oncology
Program
• Stage 1 activity screening complete under
the Company’s Autoimmune Disease
Program
Therapeutic Catalysts
Inflammatory Bowel
Disease Program
Dec 2023 MAP315 Phase I
clinical trial data readout
Immuno-Oncology
Program
H1 2024 Pre-clinical biology
and lead candidate selection complete
Testing Services Catalysts
Sonic distribution
agreements
for UK and US
Major international
launches for MetaXplore™
and MetaPanel™
•
United Kingdom
•
Europe
Autoimmune
Disease Program
•
United States
H1 2024 Stage 2 activity
screening complete
Invivo Healthcare
integration and growth
2
Disclaimer
This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba).
Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any
obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in
evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act).
Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including
industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy.
Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above.
Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is
not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you
should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws.
Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been
prepared without taking into account your investment objectives, financial situation, medical or any other particular needs This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this
Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment
objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended.
Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial
or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and
other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect",
"intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forwardlooking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking
statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of
Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results,
performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at
the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking
statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.
Financial data – All dollar values in Australian dollars (A$ or $) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for
illustrative purposes only and is not represented as being indicative of Microba’s views on its future financial condition and/or performance.
Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in
this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.
Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or
damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency,
accuracy, reliability or completeness of this Presentation.
3
Two core business segments driven by a proprietary databank
Services
Databank
Therapeutics
Proprietary
databank
Customer
Testing
Microba provides testing
and data analysis for a fee
to clinicians, consumers
and research customers
Data
Health Data
Biome Data
Driving discovery of novel
therapeutic leads
Insights
Novel
Therapies
Data-driven therapeutics
platform developing
novel monoclonal microbial
cell therapies
4
Company Snapshot
Continuous YoY
revenue growth over
5 years of operations
Partnerships with market leaders
incl. Sonic Healthcare (ASX: SHL),
Ginkgo Bioworks (NYSE: DNA),
SYNLAB (GR:SYAB) + more
Large, unique, proprietary
microbiome databank
3 key therapeutic programs
with lead IBD drug
candidate in Phase I trial
read out expected Dec 23
World-leading technology
in the emerging and rapidly
growing US$4.9 billion
microbiome sector1
Globally leading microbiome
expertise complemented by
drug discovery experts including
Prof. Ian Frazer
1 Frost & Sullivan market report – Growth Opportunities in Human Microbiome Market Forecast to 2023 – Prepared November 2019
5
Microbiome Services
Driving global revenues
and data growth
6
| Recent Highlights – Testing Services
MetaXplore launch and growth in Australia
Strong uptake and continued growth of MetaXplore™ sales in
Australia following it’s launch.
MetaPanel progressing to launch in Australia
Microba’s advanced infectious disease testing technology
MetaPanel™ progressing to launch in Australia with Sonic Healthcare
(ASX: SHL) targeting first test delivery before end of Q2 FY24.
Further European expansion
New agreement executed with SYNLAB to deliver Microba’s testing
into Norway, Serbia and additional European countries.
7
Advanced microbiome testing addressing large markets
in healthcare
Addressable Healthcare Markets
Gastrointestinal disorders
Gastrointestinal infection
Is the microbiome contributing to the patients
DGBI and how can they manage?
Does the patient have a pathogen and how can I
selectively treat it?
150M est. addressable patients worldwide1
16M est. addressable patients worldwide2
Well established out of pocket private pay
market
Well established hospital direct-bill and path
to reimbursement
1Estimated based on the prevalence of specific Disorders of the Gut-Brain Interaction across 26 countries (Av prevalence of 32.8% DOI: 10.1111/nmo.14594), and the proportion regularly seeking medical support with one or more doctor visit per month (Average
15.4% - DOI: 10.1053/j.gastro.2020.04.014)
2 Estimated based on the global number of immuno-compromised patients and other patients at high risk for gastrointestinal infection (>8.1m chemotherapy treated solid tumor cancer patients and >1.1m haematological cancer patients
DOI::https://doi.org/10.1016/S1470-2045(19)30163-9), (>3m dialysis patients DOI: 10.1038/s41581-022-00542-7), (>140k Organ Transplant patients per year https://www.transplant-observatory.org/), (>3.5m long stay ICU patients – estimate based on data from
https://ourworldindata.org/grapher/intensive-care-beds-per-100000 )
8
Significant international distribution
Partners provides access into 35 countries with 16 now operational
Strategic acquisition
unlocking a geographical
base and laboratory in
the UK, supporting the
next phase of Microba’s
international growth
strategy.
Operating Team and/or Laboratory Centre's
Contracted partner/s operational
Access via current distribution partners
9
| UK Strategic Aquisition
10
| Invivo has a strong brand, reputation, and team
• Pioneer in UK microbiome testing services
• Established a strong brand with healthcare
professionals
• Self-funded with positive operating cashflow
Multiple growth opportunities exist
before introducing Microba synergies
•
Continued growth acceleration in Vaginal
microbiome testing revenue with 40% growth in
FY23.
•
New targeted interventions are in late-stage
development to address clinician and patient
needs.
•
The integrative healthcare market is expanding
as clinicians move to private practice due to
pressure on the NHS.
•
Small sales team which is positioned for
expansion with significant opportunity to
accelerate growth.
• Positioned for growth acceleration
• Experienced and well-credentialed team
Laboratory - Bristol
•
•
•
10 staff
PCR laboratory
CL2 laboratory
Headquarters - Stroud
•
•
•
23 staff
Finance, sales and marketing
Customer service & clinical support
11
| Taking a leading position in the UK market
Invivo together with our Sonic Healthcare partnership provides Microba with deep access
to the entire UK healthcare market spanning private practice and the public NHS environment
UK TARGET HEALTHCARE MARKET
2k
Capturing the integrative
healthcare market
Driving broad adoption
into general practice,
specialists & hospitals
8k
• Leading microbiome testing
company targeting integrative
healthcare practitioners
>49k
• Est. 10k integrative healthcare
professionals in the UK*
10k
• Growth market – more people
seeking out private health
services in the UK
healthcare
professionals
• Leading medical diagnostics
company in the UK
• Preparing to deliver MetaXplore and
MetaPanel
• Addressable UK target practitioners:
- 25k General Practitioners^
- 10k Clinical dieticians^
- 4.7k Specialists positioned to
adopt microbiome testing^
25k
5k
• Customers positioned to adopt
Microba’s MetaXplore testing
GP
Specialists
Dieticians
Nutritionist
Integrative GP
* British Association for Nutrition and Lifestyle Medicine has 3,500 practicing members, Association of Nutrition has 4,400 nutritionist members, and there are an estimated 2,000 practicing integrative Medical Doctors in the UK
12 on file.
^ 4,702 specialists covering Infectious Disease, Gastroenterology, Clinical Oncology, Transplant, Nephrology and Intensive care. 27,246 General Practice Doctors minus 2,000 estimated integrative General Practitioners. Approximately 10,000 registered dieticians. References
| Invivo acquisition provides strong UK customer base
FY23
Key metrics
7,300+ tests sold
Engaged customer base
17% penetration into the UK integrative
healthcare professional market and well
positioned to accelerate growth
1,700+ ordering HCPs^
94%
of revenue
driven by repeat
customers#
51%
A$8.9m revenue*
Gross Profit
Margin
10,000+ sample biobank
Remaining market
Invivo customer
Invivo engaged lead
* *AUDGBP FX conversion rate of 0.52, Invivo has a financial year-end of 30 March, this number is pro-forma to Australian financial year-end, 30 June.
# 55.5% of healthcare practitioners (HCP) ordered more than once in the last twelve months, these repeat customers are responsible for 94% of HCP revenue
^ HCPs is an abbreviation of Healthcare Professionals
13
| Strengthening Invivo's position in GI microbiome testing
A platform for UK market entry and growth of Microba’s MetaXplore™ test
79%
of Invivo’s testing
revenue is through
their GI products*.
“From our leading position in market, we expect Microba’s world leading
MetaXplore™ will become the most favoured microbiome test for healthcare
professionals in the UK” Debbie Cotton – Head of Clinical Innovation, Invivo
• Current leading GI testing product for UK
healthcare professionals
• Next generation advanced GI test using Microba’s
world leading metagenomic technology
• Featuring 7 host markers, 62 microbial markers
• Microbiome analysis via multiplex PCR
• Includes 7 host markers, 28,000 microbial markers,
19 microbiome functions
• Offers static PDF reports
• Offers both static PDF and interactive digital reports.
19%
growth in GI testing
revenue in FY23^
14
Microbiome Therapeutics
Developing novel monoclonal
microbial cell therapies
15
A therapeutic revolution.
Novel, precision microbiome therapeutics
Precision Microbiome Therapeutics
Precision microbiome analysis platform delivering
unparalleled accuracy, coverage & depth.
Data driven discovery platform utilising one of
the worlds most advanced & highly curated
microbiome datasets.
Next generation approach to microbiome drug
development identifying single keystone species
and their biology to develop Live Biotherapeutics.
Microba Partners
Innovative Pipeline
Excellent safety profile
Scalable GMP manufacturing for high dose oral delivery
Potent and novel biology mediated by Live Biotherapeutic strategy
Strong Corporate Profile
US Pharmaceutical Executive leadership
Technically robust multi-disciplinary team
Global partners
Team Experience
16
| Rapid progress tapping the therapeutic potential of the
human microbiome for major chronic diseases
Inflammatory Bowel Disease
Immuno-Oncology Program
Autoimmune Diseases
PHASE I IN PROCESS
PRECLINICAL
SCREENING
Recently Completed
Recently Completed
Recently Completed
Phase I HREC approval
Leads discovered
Program commenced
cGMP manufacturing complete
Leads isolated
Strains provided to Ginkgo
Phase I trial commenced
First animal model results
First in vitro screening results
Phase I participant dosing complete
Stage 1 activity screening complete
Upcoming milestones
Upcoming milestones
• Immunological pre-clinical results
Upcoming milestones
• Phase I complete
• Lead candidate selection
• Stage 2 activity screening complete
17
| Recent Highlights
Inflammatory Bowel Disease Program
MAP315 Phase I all patients dosed. Positive MOA data generated.
Dosing and all patient visits successfully completed. Preliminary blinded data indicates that MAP315 is well tolerated. Multi-modal
mechanism of action (MOA) data generated for MAP315. Results remain on track for Dec 2023.
Immuno-Oncology Program
Confirmed potent anti-tumour activity.
Second mouse model demonstrated again that Microba’s therapeutic leads significantly reduce tumour burden. Further, immunological
studies demonstrated activity consistent with induction of a specific and targeted immune response. Additional animal studies and
immune profiling experiments are continuing with further data expected in Q2 FY24.
Autoimmune Disease Program
Primary screening 100% complete.
Stage 1 activity screens complete with 62% of strains demonstrating significant immunomodulatory activity and a further 18%
significantly impacting the inflammasome. 36 strains have now progressed into Stage 2 functional screening for expected completion in
Q4 FY24 to enable lead candidate selection.
18
Repeatable, scalable, data-driven platform discovering novel
monoclonal microbial cell therapies
Population
testing
Identify
groups
Healthy
AI & Advanced
Biostatistics
Monoclonal
microbial
drug lead
Disease
Proprietary microbiome databank driving multiple therapeutic
opportunities through a capital light platform
Disease
Models
Orally administered, healthy
human donor derived,
monoclonal bacterial cell
drug opportunity
19
The start of a therapeutic revolution
1 First Generation
Fecal Doner Derived
2 Second Generation
Bacterial Consortia
FDA approval Nov 30 2022
Feacal doner derived enema
drug product
Vedanta Biosciences
Vedanta Biosciences Raises
$106.5M in Funding
FDA approval April 27 2023
Feacal doner derived oral
capsule drug product
SER-155
Phase 1b showing engraftment
reduction in pathogens
3 Next Generation
Single Strain & Small Molecule
MAP315
Phase I – Ongoing, readout
expected December 2023
20
| Executing towards pharmaceutical out-licensing transactions
Recent IBD and microbiome deals
Licensee / Acquiror
Licensor / Target
Date
Type
Deal size
Indication / clinical stage
Apr 2023
Acquisition
Total deal size: US$10.8b
Ulcerative Colitis (phase 2) Crohn’s
disease (phase 2A) Autoimmune
diseases (phase I or pre clinical)
July 2022
R&D
collaboration
and license
agreement
Total deal size: Undisclosed
Upfront: €40m
Sales / regulatory milestones:
Undisclosed
Food allergies and IBD (pre clinical)
Mar 2022
Acquisition
Total deal size: US$6.7b
Ulcerative Colitis (FDA Approved,
2023), Crohn’s disease (phase2/3),
Atopic dermatitis (phase 2 complete)
Nov 2021
R&D
collaboration
and license
agreement
Total deal size: US$605m
Upfront: US$15m
Additional payments: US$590m
IBD (Discovery)
Jul 2021
Licensing
agreement in
US/Canada
Total deal size: US$525m
Upfront: US$175m
Sales / regulatory milestones: Up
to US$225m
Recurrent Clostridioides difficile
infection (Phase 3)
https://www.merck.com/news/merck-strengthens-immunology-pipeline-with-acquisition-of-prometheus-biosciences-inc/
https://www.enterome.com/news-events/enterome-signs-major-strategic-rd-collaboration-with-nestle-health-science-to-develop-and-commercialize-new-allermimics-and-endomimics-immunotherapies-for-food-allergies-and-inflamm/
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-arena-pharmaceuticals
http://novomebio.com/wp-content/uploads/2021/11/Novome-and-Genentech-Enter-into-Strategic-Collaboration.pdf
https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-nestle-health-science-announce-ser-109-co
21
Outlook
22
Milestones for 2023
2023
JAN – MAR
2023
APR - JUN
Services
Services
New healthcare product full launch
New international distribution deals
Services
Therapeutics - IBD MAP 315 program
New international distribution deals
Therapeutics - IBD MAP 315 program
Phase I HREC Submission
Therapeutics - IBD MAP 315 program
FDA Pre-IND meeting outcome
HREC Approval for Phase I trial
Therapeutics - IBD MAP 315 program
GMP manufacture complete Phase I
Therapeutics - IBD MAP 315 program
Phase I trial commencement
2023
JUL - DEC
Services
New country expansion
Services
First Sonic partners operational
Therapeutics - IBD MAP 315 program
Phase I participant dosing complete
Therapeutics - IBD MAP 315 program
Phase I complete
Therapeutics - IO Program
Therapeutics – IO Program
Therapeutics – Autoimmune Program
Therapeutics - Autoimmune Program
Pre-clinical results
First in vitro screening results
Immunological pre-clinical results
Stage 1 activity screening complete
23
Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com
Head Office
Pasquale Rombola
Level 10, 324 Queen Street
Brisbane QLD Australia
pasquale.rombola@microba.com
Laboratory
Chairman
Princess Alexandra Hospital
Woolloongabba QLD Australia
Share your feedback
Discover